Jennifer Rembisz

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer

Blaine Brower, Asia S. McCoy, Hiba Ahmad et al. · Frontiers in Oncology · 2024 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer

Jonathan Alexander Chatzkel, Michael J. Schell, Jad Chahoud et al. · Clinical Genitourinary Cancer · 2022 · 16 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).

Rohit Jain, Youngchul Kim, Jennifer Rembisz et al. · Journal of Clinical Oncology · 2022 · 12 citations

Medicine, Oncology, Pharmacology +16